Introduction {#Sec1}
============

The prevalence of smoking in the U.S. is decreasing \[[@CR1]\] and the prevalence of electronic cigarette (EC) use increasing \[[@CR2]\]. Many individuals use ECs, or vape, in effort to reduce or quit smoking \[[@CR3]--[@CR5]\]. While complete substitution of ECs for cigarettes has been associated with smoking cessation \[[@CR6], [@CR7]\], concomitant or "dual" use of ECs and cigarettes has not \[[@CR8]\], and dual use is now the most common form of EC use \[[@CR9]\]. Further, dual use has not been shown to reduce exposure to the harmful products of combustible cigarettes, including carcinogens \[[@CR10]--[@CR18]\]. The American Cancer Society, as a result, strongly discourages the dual use of EC and cigarettes \[[@CR19]\]. Additionally, recent evidence suggests that frequent vaping itself carries increased risk of cardiovascular disease \[[@CR20], [@CR21]\], and newer generation EC devices can achieve nicotine levels comparable or exceeding those of conventional cigarettes \[[@CR22]\], increasing the potential for adverse effects from nicotine.

The American Indian (AI) population in general has a very high smoking prevalence, particularly in the Plains states \[[@CR23]--[@CR26]\]. AI people also have the highest prevalence of EC use of any single-race group in the U.S. \[[@CR27], [@CR28]\]. However, use of EC by AI who smoke has been reported only rarely \[[@CR29], [@CR30]\], and the patterns and preferences of EC use among AI dual users, never. We now describe patterns, EC dependence, and preferences by focusing on the dual user subset, defined as people who smoked cigarettes and used ECs on some days or every day of the past 30 days. This common definition \[[@CR31]\] minimizes the inclusion of people who merely experimented with ECs once or twice, and allows focus on persons with more habitual EC use.

Methods {#Sec2}
=======

The "Vaping among Smokers: A Cherokee Nation Cohort Study" was designed to provide estimates of the prevalence and patterns of EC use among adult AI smokers and has been described in detail elsewhere \[[@CR30]\]. Briefly, in 2016 we recruited 375 adult AI men and women, who smoke, at a large Cherokee Nation Health Services outpatient facility in northeastern Oklahoma to participate in the study. Eligibility for services includes proof of AI or Alaska Native (AN) descent, such as a Certificate of Degree of Indian Blood (CDIB), from a federally recognized AI or Alaska Native tribe or community. Eligibility to participate in the cohort included being age 18 years or older, smoking at least 100 cigarettes in one's lifetime, smoking in the past 30 days, and answering "yes" to both "Are you American Indian?" and "Do you have a CDIB card?"

Participants completed a survey including patterns of smoking and EC use. The current cross-sectional descriptive analysis is limited to the subset of dual users as defined below.

Measures {#Sec3}
--------

All participants reported whether they ever used ECs, and if so, whether they used any in the past 30 days \[[@CR30]\]. Among these, dual users were defined as using EC on some days or every day within the past 30 days. This definition of dual use reduces the chance of including persons whose vaping was limited to curiosity or brief experimentation \[[@CR31]\].

Vaping measures {#Sec4}
---------------

Dual users reported how many times per day they used an EC (categorized as: less than 5, 5--9, 10--14, 15--19, 20--29, or 30 or more), which type of product most often used (cigalike, tank, mods, other), whether their e-liquid contained nicotine (yes, no, don't know/not sure) and the nicotine content of their usual EC product (0 mg, 1--12 mg, 13--17 mg, 18+ mg, don't know/not sure). Dual users also reported whether they enjoyed vaping more than smoking, and whether they use EC vs a cigarette first on days they use both.

Vaping dependence and smoking dependence were separately assessed using the Heaviness of Vaping Index \[[@CR32]\], Heaviness of Smoking Index \[[@CR33]\] and the Penn State Dependence Index (PSDI) for vaping or smoking \[[@CR32]\] as adapted slightly for this study ([Appendix](#Sec13){ref-type="sec"}). The Heaviness of Vaping and Heaviness of Smoking indices are two-item measures of nicotine dependence for EC users and smokers, respectively. The PSDI for vaping and PSDI for smoking are 10-item indices to measure dependence on vaping or smoking, respectively. Cases with any missing component of the index were excluded from the scoring to reduce bias towards low dependence \[[@CR32]\].

Participants indicated one or more reasons for using ECs, including to reduce cigarette smoking, liking the flavors, using when smoking is not allowed, less harmful to self than smoking, less harmful to others than smoking, reducing stress, better affordability, and/or other people important to them use ECs, or other (write in).

Analysis {#Sec5}
--------

Categorical data are represented by count (percent). Continuous data are represented using the mean (SD). Dependence scales were assessed for normality using the Shapiro-Wilk test and visual confirmation via quantile-quantile plots, then compared between vaping and smoking using paired t-tests with complete case analysis. The Shapiro-Wilk test is a commonly-applied method to assess normality assumptions underlying parametric statistical procedures \[[@CR34], [@CR35]\]. All analyses were performed using SAS software v9.4 and R v3.5.1.

Results {#Sec6}
=======

Of the 375 enrolled participants, 44 (12%) were dual users, defined as using ECs on some or all of the past 30 days.

Table [1](#Tab1){ref-type="table"} shows that among dual users, about one-third vaped 10 or more times a day, and less than one-half vaped fewer than 5 times per day. "Cigalikes" were the least frequently used product and tank systems were the most frequently used product. While 80% indicated that their e-liquid contained nicotine, 11% used e-liquid without nicotine, and 9% were unsure or did not know if their e-liquid contained nicotine. The most frequently reported nicotine content was 12 mg or less, but 14% did not know the nicotine concentration. More than half did not find vaping more enjoyable than smoking and most reported smoking before vaping on days they did both. Table 1Vaping patterns and preferences, American Indian EC dual users (*N* = 44)FrequencyFrequency of EC use per day Less than 5 times per day46% 5--9 times per day20% 10 or more times per day34%Type of EC product used most often Cigalike12% Tank68% Mods18% Other2%E-liquid contains nicotine Yes80% No11% Don't know/Not sure9%Usual E-liquid nicotine content 0 mg7% 1--12 mg39% 13--17 mg18% 18 or more mg23% Don't know/Not sure14%Enjoy vaping more than smoking Yes40% No60%On vaping days, which is used first Cigarette76% EC24%*EC* Electronic Cigarette

Vaping and smoking dependence item measures and scales are shown in Table [2](#Tab2){ref-type="table"}. Although 76% reported smoking before vaping as noted above, vaping or smoking within the first 5 min of waking was not infrequent for either habit (31% and 24%, respectively), and cumulatively, the frequency of vaping or smoking within 30 min of waking was the same (55%). Individual measures show more dependence on smoking than vaping. Heaviness of vaping index and heaviness of smoking index did not differ significantly among the dual users (*p* = 0.22), but the mean PSDI dependence score for vaping was significantly lower than that for smoking (6.4 +/− 4.8 vs 11.0 +/− 5.0, respectively; *p* \< .0001). Results were unchanged when median values of the PSDI were compared via the Wilcoxon signed-rank test (6 vs 11, *p* \< .0001). Table 2Vaping dependence and smoking dependence measures among adult AI dual EC and cigarette users (*N* = 44)Vaping Dependence Measures%Smoking Dependence Measures%Minutes after waking use first ECMinutes after waking use first cigarette 5 or less31% 5 or less24% 6--3024% 6--3031% 31--12024% 31--12038% 121+21% 121+7%Nights per week wake to use ECNights per week wake to smoke Never/less than weekly73% Never/less than weekly54% 1 to 212% 1 to 223% 3 or more15% 3 or more23%Continue using EC because hard to quitContinue to smoke because hard to quit Yes44% Yes80% No56% No20%Ever have strong cravings to use ECEver have strong cravings to smoke Yes33% Yes84% No67% No16%How strong were urges to vape, past weekHow strong were urges to smoke in past week None44% None0% Slight34% Slight18% Moderate10% Moderate25% Very/extremely strong22% Very/extremely strong57%Hard to keep from using ECHard to keep from smoking Yes36% Yes58% No64% No42%*WHEN HAVE NOT USED \[EC; tobacco\] for a while OR when you tried to stop \[vaping; smoking\] ...*Irritable because can't use ECIrritable because can't smoke Yes32% Yes73% No68% No27%Nervous because can't vapeNervous because can't smoke Yes32% Yes66% No68% No34%Composite Dependence Scores*p-*value\*Heaviness of Vaping Index \[[@CR32]\]Mean (SD)2.07 (1.76)Heaviness of Smoking Index \[[@CR33]\]Mean (SD)2.36 (1.66).2155PSDI-EC \[[@CR32]\]Mean (SD)6.42 (4.84)PSDI-smoking \[[@CR32]\]Mean (SD)11.02 (5.00)\<.0001*EC* Electronic Cigarette*PSDI* Penn State Dependence IndexMissing = 10 for Heaviness of Vaping Index, 12 for PSDI-EC, 2 for Heaviness of Smoking Index, and 3 for PSDI-smoking\*Paired t-test on the differences between the vaping dependence scores and smoking dependence scores

Reasons for vaping are shown in Fig. [1](#Fig1){ref-type="fig"}. The top three most commonly endorsed reasons for vaping were to cut down on smoking, liking EC flavors, and being able to vape in places wherein smoking is not allowed. Perceiving less harm to others or to oneself compared with smoking were the next most frequent responses. Less than one-half endorsed using EC to reduce stress, reduce cost, or because other persons important to them used EC. Other reasons (write in) for EC use were endorsed by only two (4.5%) participants. Fig. 1Reasons for vaping among American Indian dual EC and cigarette users

Discussion {#Sec7}
==========

In this cohort of adult AI persons who smoke, the prevalence of dual use, defined as using EC on some or all of the past 30 days, was 12%. This definition of dual use is similar to other longitudinal studies \[[@CR7], [@CR36]\] and helps to exclude recent experimenters or infrequent users \[[@CR31]\]. Other studies vary widely in estimates of prevalence of dual use by smokers. In a 2014 study, nearly 52% of a cohort of smokers used ECs either daily or more than just a few days \[[@CR7]\]. However, in a 2013 study, prevalence of EC use more than 50 times during lifetime was only 3.8% among smokers \[[@CR37]\] and among current smokers in the Current Population Survey in 2014, regular EC use among smokers was 3.6% \[[@CR38]\]. Definitions of dual use may vary enough to limit our ability to directly compare prevalence estimates between different cohorts, and the rapid rise in EC use also limits comparison with older studies. Standardized definitions of dual use will be useful in future studies.

Vaping patterns {#Sec8}
---------------

Vaping 10 or more times per day was reported by one-third of the dual users. Very few studies report on the frequency of vaping by dual users, and often use different measures \[[@CR39]\]. Given the continued debate regarding utility of EC in smoking cessation \[[@CR40]\] and evidence of no clear benefit of dual EC and cigarette use \[[@CR17]\], frequency of vaping needs more exploration by this group of smokers. Again, standardization of measures of vaping frequency will help in comparing future studies.

First generation (cigalike) ECs were the least often used products and the second-generation "tank" products the most often used. Second- and third-generation products allow users to customize their product, unlike the first generation cigalikes \[[@CR41]\], in ways that likely improve the nicotine delivery \[[@CR22], [@CR42]\].

Nicotine content of vaping products among dual users {#Sec9}
----------------------------------------------------

While the majority of participants used ECs that contained nicotine, nearly 20% either did not or were unsure if they did. In another study, of 399 adult EC users who were current smokers in 2015, 337 (80.7%) used EC containing nicotine, with 19% not \[[@CR43]\]. While many smokers who also use ECs do so to reduce smoking, several EC users did not know the nicotine content of their EC product, or even if the product contained nicotine. If ECs are to replace, rather than supplement combustible cigarettes, nicotine content may be an important factor.

### Measures of EC dependence {#Sec10}

Measures of EC dependence were relatively low compared to measures of cigarette dependence among these dual users, similar to findings in other studies \[[@CR32], [@CR39], [@CR44], [@CR45]\]. In our study, all participants were current smokers at baseline, so EC dependence among these dual users are not directly comparable to studies of exclusive EC uses. In addition, a relatively higher proportion of dual EC users had missing data for the vaping dependence scales, but the effect of this potential bias is unclear. Smoking dependence questions preceded vaping dependence questions in our survey and the similarity in questions and format may have confused participants. Whether ECs had reduced these respondents' dependence on cigarettes could not be assessed in this study.

### Reasons for vaping {#Sec11}

Flavoring was the most often endorsed reason for vaping. The impact of flavoring has never been reported for AI who smoke and use ECs. The role of flavoring in use of EC products is of increasing interest. A recent study found that flavors influenced nicotine exposure through flavor liking, but also contributed to heart rate acceleration, and nicotine titration \[[@CR46]\]. In the US, sales of flavored EC products have greatly increased, including in Oklahoma \[[@CR47]\]. In one study, adult smokers' interest in flavored EC was modest, but among the smokers who also use ECs, EC use was most affected by flavor \[[@CR48]\]. In contrast, flavoring was only infrequently (14.7%) cited as a reason for EC use by current smokers in a national survey \[[@CR5]\].

Other than using EC to stop smoking, the convenience of vaping in places where smoking was not allowed was another leading reason for vaping. More than half cited their perception of EC being less harmful to others, and stress, affordability, or others' vaping were among the least common. Reasons for dual use of EC among smokers usually include desire to quit smoking \[[@CR49], [@CR50]\], and perceptions of less harm than cigarettes \[[@CR49], [@CR51]\], but other factors are less frequently assessed.

### Limitations {#Sec12}

A small, convenience and clinic-based sample limits our study. In addition, patterns of tobacco use vary across AI communities in the US, and findings from this study may not reflect use in other regions. Nonetheless, this pilot study took place in a region with high prevalence of tobacco use and provides a unique snapshot of AI dual users and their vaping habits. Larger, population based studies will greatly help to elucidate regional differences in the effects of ECs upon the smoking habits of AI people. As EC technology continues to evolve rapidly, the types of EC products used in 2016 may not reflect currently used EC products. Follow up studies are needed to assess changes in use over time.

Appendix {#Sec13}
========

The Penn State Electronic Cigarette Dependence Index \[[@CR32]\] as adapted for this study. How many times per day do you usually use your electronic cigarette? (Scoring: 0--4 times/day = 0, 5--9 = 1, 10--14 = 2, 15--19 = 3, 20--29 = 4, 30+ = 5),How soon after you wake up do you first use your e-cig or vape? (Scoring: 0--5 min = 5, 6--15 = 4, 16--30 = 3, 31--60 = 2, 61--120 = 1, 121+ = 0),Do you sometimes awaken at night to vape or use your e-cig? (Yes = 1, No = 0),How many nights per week do you typically wake up to vape or use your e-cig? I never wake up at night to vape, less than one night per week, 1 night per week, 2 nights per week, 3 nights per week, 4 or more nights per week. (Scoring 0--1 nights = 0, 2--3 nights = 1, 4+ nights = 2)Do you vape or use an e-cig now because it is really hard to quit? (Yes = 1, No = 0)Do you ever have strong cravings to use an e-cig or vape? (Yes = 1, No = 0)Over the past week, how strong have the urges to vape or use an e-cig been? None, slight, moderate, strong, very strong, extremely strong. (Scoring: None/slight = 0, Moderate/Strong = 1, Very Strong/Extremely strong = 2)Is it hard to keep from using an e-cig or vaping in places where you are not supposed to, such as restaurants, hospital/clinics, or other public areas? (Yes = 1, No = 0)When you haven't used an e-cig or vaped for a while or when you tried to stop ... Did you feel more irritable because you couldn't vape or use an e-cig? (Yes = 1, No = 0)When you haven't used an e-cig or vaped for a while or when you tried to stop ... Did you feel nervous, restless, or anxious because you couldn't vape or use an e-cig? (Yes = 1, No = 0)
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